Bone Biologics Corporation
BBLG | NASDAQ
$0.48
-$0.04 (-7.51%)
Sep 21, 2026, 4:00 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -3.23M | -4.22M | -9.43M | -3.67M | -1.1M | -825.01K |
Interest Income | 121.98K | 55.66K | 1.87K | n/a | 805.11 | 998.08 |
Pretax Income | -3.11M | -4.11M | -8.95M | -1.48M | -1.61M | -1.82M |
Net Income | -3.11M | -4.11M | -8.95M | -1.48M | -1.61M | -1.82M |
Selling & General & Admin | 2.17M | 2.09M | 2.52M | 2.09M | 1.02M | 484.34K |
Research & Development | 1.06M | 2.13M | 6.91M | 1.58M | 82.04K | 340.67K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 3.23M | 4.22M | 9.43M | 3.67M | 1.1M | 825.01K |
Interest Expense | n/a | n/a | n/a | 731.71K | 805.11K | 998.08K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.23M | 4.22M | 9.43M | 3.67M | 1.1M | 825.01K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | 1.6K |
Shares Outstanding (Basic) | 1.17M | 1.52M | 263.14K | 47.6K | 43K | 51K |
Shares Outstanding (Diluted) | 1.17M | 1.52M | 263.14K | 47.66K | 43.13K | 51.14K |
EPS (Basic) | -2.65 | -4.83 | -34.01 | -31.15 | -37.35 | -35.68 |
EPS (Diluted) | -2.65 | -4.83 | -34.01 | -31.20 | -37.35 | -35.68 |
EBITDA | -3.11M | 107.16K | 479.57K | -752.91K | -805.58K | -825.01K |
EBIT | -3.11M | -4.11M | -8.95M | -752.91K | -805.58K | -825.01K |
Depreciation & Amortization | n/a | 4.22M | 9.43M | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove BBLG